Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Info & Links
CEO
Alfred Sandrock
Headquarters
75 HAYDEN AVENUE LEXINGTON, MA 02421, UNITED STATES
Voyager Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
220.14M
Enterprise Value
107.62M
Enterprise Value/EBITDA(ttm)
18.30
Price to Earnings Ratio(ttm)
6.00
Price to Sales(ttm)
1.42
Price to Book(mrq)
0.70
Price to Cash(ytd)
1.41
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
15.80%
Profit Margin(ttm)
-16.61%
Return on Equity(ttm)
8.33%
Return on Invested Capital(ttm)
14.78%
Return on Assets(ttm)
6.15%
Income Statement
Revenue(ttm)
163.78M
Revenue Per Share(ttm)
3.00
Gross Profit(ttm)
163.78M
EBITDA(ttm)3
5.88M
Net Income Available to Common(ttm)
25.88M
Diluted EPS(ttm)
0.71
Share Statistics
Beta (5Y Monthly)
0.91
52-Week Change
-58.70%
S&P 500 52-Week Change
14.01%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
54.63M
Dividend Yield
0.00%
Float4
52.15M
% Held by Insiders
4.53%
% Held by Institutions
48.03%
Balance Sheet
Total Cash(mrq)
345.36M
Total Cash Per Share(mrq)
6.32
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
8.45%
Quick Ratio(mrq)
8.45%
Book Value Per Share(mrq)
6.06
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.01
Free Cash Flow(ytd)
-4.15M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.